Mannie, Mark D.Curtis II, Alan Dale2016-06-162016-06-162013-05Human Vaccines & Immunotherapeutics; 9:5 p. 1032-10382164-5515http://hdl.handle.net/10342/5655Tolerogenic vaccines represent a new class of vaccine designed to re-establish immunological tolerance, restore immune homeostasis, and thereby reverse autoimmune disease. Tolerogenic vaccines induce long-term, antigen-specific, inhibitory memory that blocks pathogenic T cell responses via loss of effector T cells and gain of regulatory T cell function. Substantial advances have been realized in the generation of tolerogenic vaccines that inhibit experimental autoimmune encephalomyelitis in a preclinical setting, and these vaccines may be a prequel of the tolerogenic vaccines that may have therapeutic benefit in Multiple Sclerosis. The purpose here is to provide a snapshot of the current concepts and future prospects of tolerogenic vaccination for Multiple Sclerosis, along with the central challenges to clinical application.autoimmune diseaseexperimental autoimmune encephalomyelitisimmunemultiple sclerosismyelinneuroantigenT lymphocytestherapytolerancevaccineArticlepmc389913710.4161/hv.23685